Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin.

Literature DB >> 1659309

In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin.

Abstract

MICs of azithromycin and erythromycin for 20 Campylobacter coli and 20 Campylobacter jejuni strains were determined. The results demonstrated that, for Campylobacter species, all high-level erythromycin-resistant strains were also resistant to azithromycin and that azithromycin did not exhibit increased potency in comparison with that of erythromycin.

Entities: Chemical Species

Mesh：

Substances：
Erythromycin
Azithromycin

Year: 1991 PMID： 1659309 PMCID： PMC245292 DOI： 10.1128/AAC.35.9.1917

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

1. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors: J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal: Antimicrob Agents Chemother Date: 1987-12 Impact factor: 5.191

2. Macrolide, lincosamide and streptogramin resistance in Campylobacter jejuni/coli.

Authors: R Burridge; C Warren; I Phillips
Journal: J Antimicrob Chemother Date: 1986-03 Impact factor: 5.790

3. Erythromycin-resistant Campylobacters.

Authors: M Walder; A Forsgren
Journal: Lancet Date: 1978-12-02 Impact factor: 79.321

4. Susceptibility of Campylobacter fetus subsp. jejuni to twenty-nine antimicrobial agents.

Authors: R Vanhoof; M P Vanderlinden; R Dierickx; S Lauwers; E Yourassowsky; J P Butzler
Journal: Antimicrob Agents Chemother Date: 1978-10 Impact factor: 5.191

5. In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria.

Authors: M D Kitzis; F W Goldstein; M Miégi; J F Acar
Journal: J Antimicrob Chemother Date: 1990-01 Impact factor: 5.790

6. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors: R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal: Antimicrob Agents Chemother Date: 1989-03 Impact factor: 5.191

7. Antimicrobial susceptibility of Campylobacter jejuni with special reference to resistance patterns of Canadian isolates.

Authors: M A Karmali; S De Grandis; P C Fleming
Journal: Antimicrob Agents Chemother Date: 1981-04 Impact factor: 5.191

8. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors: G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal: J Antibiot (Tokyo) Date: 1988-08 Impact factor: 2.649

9. Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli.

Authors: W L Wang; L B Reller; M J Blaser
Journal: Antimicrob Agents Chemother Date: 1984-09 Impact factor: 5.191

10. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors: D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal: Antimicrob Agents Chemother Date: 1988-11 Impact factor: 5.191

10 in total

9 in total

1. Development of resistance to macrolide antibiotics in an AIDS patient treated with clarithromycin for Campylobacter jejuni diarrhea.

Authors: G Funke; R Baumann; J L Penner; M Altwegg
Journal: Eur J Clin Microbiol Infect Dis Date: 1994-07 Impact factor: 3.267

In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin.

1. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

2. Macrolide, lincosamide and streptogramin resistance in Campylobacter jejuni/coli.

3. Erythromycin-resistant Campylobacters.

4. Susceptibility of Campylobacter fetus subsp. jejuni to twenty-nine antimicrobial agents.

5. In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria.

6. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

7. Antimicrobial susceptibility of Campylobacter jejuni with special reference to resistance patterns of Canadian isolates.

8. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

9. Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli.

10. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

1. Development of resistance to macrolide antibiotics in an AIDS patient treated with clarithromycin for Campylobacter jejuni diarrhea.

2. In vitro susceptibility of quinolone-resistant Campylobacter jejuni to new macrolide antibiotics.

3. In vitro activity of azithromycin against bacterial enteric pathogens.

4. Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides.

5. Intracellular activity of azithromycin against bacterial enteric pathogens.

6. Azithromycin resistance in Campylobacter jejuni and Campylobacter coli.

7. Molecular Basis of Macrolide Resistance in Campylobacter Strains Isolated from Poultry in South Korea.

8. Chronic Lyme Disease and Co-infections: Differential Diagnosis.

9. Prevalence of Campylobacter species in milk and milk products, their virulence gene profile and anti-bio gram.